Aim: To evaluate if patients with Mal de Debarquement syndrome (MdDS) demonstrate different symptom levels or symptom type during pregnancy.
Materials & Methods: 18 MdDS patients that were or had been pregnant during their condition were recruited to complete a retrospective online questionnaire. Respondents answered questions regarding their basic clinical data, diagnosis, triggers and differences in symptom level and symptom type during pregnancy and before pregnancy.
Results: A total of 81.3% reported that their symptoms were reduced during pregnancy compared with before pregnancy. Respondents also reported a different perception of motion and experienced less dizziness while being pregnant.
Conclusion: The physiological changes that occur during pregnancy improve the symptoms of patients with MdDS, and this is potentially attributable to the rise in estrogen and progesterone.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511939 | PMC |
| http://dx.doi.org/10.4155/fsoa-2018-0109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Photodynamic Therapy with Protoporphyrin IX Precursors Using Artificial Daylight Improves Skin Antisepsis for Orthopedic Surgeries.
Microorganisms
January 2025
Department of Dermatology, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland.
Classical preoperative skin antisepsis is insufficient in completely eliminating bacterial skin colonization for arthroplasty. In contrast, photodynamic therapy (PDT) with red light and methyl-aminolevulinate (MAL), combined with skin antisepsis, led to the absence of bacterial growth in healthy participants, though with local skin erythema, posing an obstacle for orthopedic surgery. Therefore, we explored whether artificial daylight PDT (PDT-DL) was superior to red light.
View Article and Find Full Text PDFCardiogenic shock in patients with active onco-hematological malignancies: A multicenter retrospective study.
J Crit Care
January 2025
Hospital Saint-Louis et Université Paris Cité, Assistance Publique-Hôpitaux de Paris, France. Electronic address:
Purpose: Onco-hematological (OH) patients face significant cardiovascular risks due to malignancy and drug toxicity. Data are limited on the characteristics and outcomes of OH patients with cardiogenic shock (CS) in intensive care units (ICUs).
Methods: This multicenter retrospective study included 214 OH patients with CS across 22 ICUs (2010-2021).
Safety of two-dose schedule of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan) and heterologous additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised and immunocompetent individuals.
Rev Inst Med Trop Sao Paulo
January 2025
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Clínica de Moléstias Infecciosas e Parasitárias, Laboratório de Investigação Médica em Imunologia (LIM-48), SSão Paulo, São Paulo, Brazil.
Immunocompromised individuals were considered high-risk for severe disease due to SARS COV-2 infection. This study aimed to describe the safety of two doses of COVID-19 adsorbed inactivated vaccine (CoronaVac; Sinovac/Butantan), followed by additional doses of mRNA BNT162b2 (Pfizer/BioNTech) in immunocompromised (IC) adults, compared to immunocompetent/healthy (H) individuals. This phase 4, multicenter, open label study included solid organ transplant and hematopoietic stem cell transplant recipients, cancer patients and people with inborn errors of immunity with defects in antibody production, rheumatic, end-stage chronic kidney or liver disease, who were enrolled in the IC group.
View Article and Find Full Text PDF[Elexacaftor, Tezacaftor and Ivacaftor: immediate efficacy evaluation using home spirometry].
Rev Mal Respir
January 2025
Unité de pneumologie adulte, centre de mucoviscidose liégeois, CHC MontLégia, Liège, Belgique.
Introduction: Following two weeks of application of the triple combination therapy of Elexacaftor (E), Tezacaftor (T), and Ivacaftor (I) known as ETI, substantial pulmonary improvement in patients with cystic fibrosis is well-documented. However, few detailed data are available on the action of this treatment over the course of these first 14 days.
Methods: In this prospective study (NCT05599230), 20 patients aged≥12 years, all of them eligible for ETI, were recruited at the initiation of treatment.
[Factors associated with venous thromboembolism in tuberculosis patients in Burkina Faso: A case control study].
Rev Mal Respir
January 2025
Service de pneumologie, CHU Yalgado Ouédraogo, 01 BP 730, Ouagadougou, Burkina Faso.
Introduction: The mortality caused by tuberculosis is partially explained by co-morbidities such as venous thromboembolic disease. Our study was aimed at identifying the factors associated with venous thromboembolism in tuberculosis patients.
Methods: This was a case-control study of patients with pulmonary tuberculosis with or without venous thromboembolic disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!